一个罕见的Tirzepatide诱导的肝毒性病例
Aalam Sohal1, Luis Casanova1, Kris V Kowdley1,2
1Department of Hepatology, Liver Institute Northwest, Seattle, WA.
ACG case reports journal
|October 7, 2024
概括
治疗糖尿病和肥胖症的药物蒂尔泽帕提德 (Tirzepatide) 与患有代谢综合征的患者肝酶升高有关. 这一案例突出了提泽帕提德治疗的潜在,以前未报告的副作用.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 蒂尔泽帕提德是一种新型的双素受体激动剂,已被批准用于2型糖尿病和肥胖症.
- 它在降低肝脏脂肪含量方面已证明有好处.
- 此前没有记录过特泽帕提德诱导的肝损伤病例.
研究的目的:
- 报告一种可能与蒂尔泽帕提德使用相关的肝酶升高病例.
- 为了突出蒂尔泽帕提德在代谢综合征患者中可能产生的不良影响.
主要方法:
- 一个37岁的女性患有代谢综合征的病例报告.
- 在 Tirzepatide 治疗期间监测肝酶.
主要成果:
- 患者在提尔泽帕提德治疗期间肝酶水平升高.
- 这一发现表明药物的潜在肝毒性作用.
结论:
- 蒂尔泽帕提德可能会导致肝酶升高,这是以前未报告的不良反应.
- 建议密切监测肝功能,为患者在提尔泽帕提德,特别是那些有代谢综合征.
相关概念视频
Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
100
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
Drug Toxicity: Risk factors
248
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248
Drug Toxicity: Allergic Reactions
223
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
223
Drug toxicity: Idiosyncratic Reactions
232
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
232
Hepatic Encephalopathy
71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71


